US LNG exports surge but will buyers in China turn up?
Rodney James Williams, a director at Zomedica Corp. (AMEX:ZOM), recently acquired 100,000 shares of the company’s common stock. The purchase, executed on March 17, 2025, was made at a price of $0.069 per share, totaling $6,900. The transaction comes as InvestingPro data shows the stock trading in oversold territory, with shares down significantly over the past three months. Following this transaction, Williams holds 261,900 shares directly. Additionally, he has an indirect ownership of 40,000 shares through an IRA managed by Entrust Group. This acquisition was part of a correction to a previous filing to accurately reflect Williams’s total beneficial ownership of Zomedica stock. According to InvestingPro analysis, Zomedica maintains a strong balance sheet with more cash than debt, and its overall financial health is rated as FAIR. For deeper insights into Zomedica’s valuation and comprehensive analysis, investors can access the detailed Pro Research Report, available exclusively on InvestingPro.
In other recent news, Zomedica Pharmaceuticals (NYSE:ZOM) Corp reported its fourth-quarter 2024 earnings, revealing a revenue of $7.9 million, which signifies an 8% increase from the previous year. Despite a net loss of $7.2 million, the company maintained robust gross margins of 70.3% and a strong cash position with $71.4 million in liquidity. The company has set a goal to achieve cash flow breakeven at a $50 million run rate. In addition to its financial performance, Zomedica is focusing on expanding its presence in the equine and international markets, which is expected to drive future growth.
The company also announced a new distribution agreement with Crestlon for the Betagel hemostatic gel product line, marking its expansion into new care areas within veterinary practices. Meanwhile, Zomedica continues to explore strategic options to enhance its share price, following its recent delisting from the NYSE American Exchange. The company has transitioned to the OTCQB market, ensuring uninterrupted trading for its shareholders. Additionally, Zomedica plans to engage investors through monthly webinars to highlight its innovative product portfolio and strategic vision.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.